In an interview at the recent RSNA conference, Catherine Everett, M.D., shared her perspective on the radiology workforce shortage, offered insights on recruiting radiologists to rural areas and emphasized the urgency of bolstering access to radiologists and other health-care professionals for at-risk communities.
Amid a sea of subspecialty expectations, recruiting challenges and coverage issues, staying on top of imaging volume that has spiked 20 percent since the COVID-19 pandemic has become nearly insurmountable, noted Catherine Everett, M.D., during a recent interview at the Radiological Society of North America (RSNA) conference.
“Now when we leave (at the end of the day), the list is nowhere near over,” explained Dr. Everett, the president and managing partner of Coastal Radiology in New Bern, N.C. “People are working at night and people are working extra on weekends. … We have radiologists who are getting burned out and are thinking about quitting. That is a real issue for my practice.”
In regard to recruiting radiologists for a rural setting, Dr. Everett advocates a more targeted approach that emphasizes a community lifestyle and family. Accordingly, she noted that her practice usually targets smaller residency programs or private practice programs in which residents do a fair amount of work and can hit the ground running.
(Editor’s note: For related content, see “Overcoming Burnout in Radiology,” “Has Burnout Become an Epidemic in Radiology?” and “The Reading Room Podcast: Emerging Trends in the Radiology Workforece.”)
Now more than ever, radiologists and other health care workers are urgently needed to help preserve access to rural health facilities for communities that tend to be poorer, older and have more comorbidities, according to Dr. Everett, the associate chief medical officer for practice analytics at Radiology Partners.
“Twenty-three percent of the rural population meets the criteria for lung cancer screening compared to 15 percent of the urban community. Yet only 22 percent of the rural population is within an hour of a screening facility and 83 of the urban population is. … It’s a huge issue not only with disease but also with access,” noted Dr. Everett.
For more insights from Dr. Everett, watch the video below.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.